

Update on statin-mediated anti-inflammatory activities in atherosclerosis

Fabrizio Montecucco · François Mach

Received: 18 March 2009 / Accepted: 15 April 2009 / Published online: 5 May 2009
© Springer-Verlag 2009

Abstract Anti-inflammatory activities of statins in atherosclerosis have been well documented by both basic research and clinical studies. Statins have been introduced in the 1980s as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to block cholesterol synthesis and lower cholesterol serum levels. In the last three decades, statins have been shown to possess several anti-inflammatory and antioxidant activities resulting in the beneficial reduction of atherosclerotic processes and cardiovascular risk in both humans and animal models. Inflammatory intracellular pathways involving kinase phosphorylation and protein prenylation are modulated by statins. The same intracellular mechanisms might also cause statin-induced myotoxicity. In the present review, we will update evidence on statin-mediated regulation of inflammatory pathways in atherogenesis.

Keywords Statin · Atherosclerosis · Inflammation · Kinases · Cholesterol

Introduction

Cardiovascular diseases are the leading cause of death and disability in the adult population of developed and developing

countries [1–3]. In the majority of patients, clinical cardiovascular disease is the final step of the inflammatory state characterizing atheroprogession. Stable advanced atherosclerotic plaques mainly induce chronic arterial lumen stenosis and ischemia in peripheral tissues. This condition causes chronic organ remodeling and alters their functions. In the heart, chronic hypoxia can induce congestive heart failure (CHF). On the other hand, unstable plaques frequently progress to rupture with the consequent exposure to the blood lumen of intraplaque prothrombotic material. In that case, thrombus causes the sudden complete occlusion of the arterial lumen, and peripheral tissues are exposed to acute ischemia. If collateral arteries are not present and acute ischemia is prolonged, tissue necrosis can occur with dramatic consequences in the heart and brain. Several cardiovascular risk factors have been associated with CVD. More than 50 years ago, this concept was introduced by the Framingham Heart Study, with the identification of major coronary heart disease (CHD) risk factors, such as hypertension, hyperlipidemia, smoking, and diabetes [4]. However, although highly sensitive, these traditional factors showed a very low specificity [5–7]. Therefore, inflammatory soluble mediators, which have been shown to play a central role in all phases of atherosclerosis, have been investigated [8–10] with some preliminary encouraging results. In particular, the American Heart Association (AHA/CDC) has recently suggested that the high sensitivity dosage of the acute phase reactant C-reactive protein (CRP) might be useful when physicians are undecided about indications of a more intensive treatment for patients who are considered at intermediate cardiovascular risk [11, 12]. At present, the most promising therapeutic strategies to reduce cardiovascular diseases are represented by the selective blockade of both “classical” and new emerging

F. Montecucco · F. Mach
Division of Cardiology, Foundation for Medical Researches,
University Hospital,
Geneva, Switzerland

F. Montecucco (✉)
Cardiology Division, Department of Medicine,
Geneva University Hospital,
Foundation for Medical Researches, 64 Avenue Roseaie,
1211 Geneva, Switzerland
e-mail: fabrizio.montecucco@unige.ch

factors promoting atherogenesis. Statins (3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors) should be considered as anti-atherosclerotic drugs capable of modulating different factors. Basic research and clinical studies have shown that statins lower LDL cholesterol levels and inhibit atherosclerotic inflammatory processes. Little is known on the possible statin-mediated molecular mechanisms to reduce cardiovascular risk. In the present review, we will focus on selective anti-inflammatory activities of members of statin family and the statin-mediated modulation of intracellular pathways in both immune and vascular cells, which play a crucial role in atherosclerosis.

Statins in cardiovascular diseases

The first identification of a fungal metabolite (compactin) blocking cholesterol synthesis has been performed in 1971 by Endo and coworkers [13]. In 1976, the “Compactin Development Project” composed by several experts started. Starting from 1978, a new statin (called lovastatin) has been discovered and developed. In 1980s, statins have been shown to lower LDL cholesterol levels in patients with hypercholesterolemia [14–18]. These first impressive results induced the US Food and Drug Administration to approve the commercial use of statins in 1986 [19]. After lovastatin, three generations of statins have been commercially introduced: pravastatin and fluvastatin (first generation), atorvastatin and simvastatin (second generation), and rosuvastatin and pitavastatin (third generation). Cerivastatin was also approved for the marketplace but was eventually discontinued for its myotoxic effects [13]. Statins have been tested in primary prevention for acute cardiovascular events in both high cardiovascular risk patients (diabetes, hypertension, and dyslipidemia) and subjects with low or no CVD risk [20–25]. For instance, aggressive treatment of diabetic subjects with statins has been shown to reduce coronary events and stroke [21–23]. This was also observed in diabetic patients with dyslipidemia [26]. The principal primary prevention study in hypertensive patients (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA)) showed that atorvastatin reduces the relative risk of primary CHD [27]. On the other hand, The Intervention Trial Evaluating Rosuvastatin (JUPITER, a large multinational, long-term, double blind, and randomized clinical trial) showed that treatment with rosuvastatin significantly reduces the incidence of major cardiovascular events in healthy subjects without hyperlipemia but with elevated high-sensitivity CRP levels [28]. Statins have been also investigated in secondary prevention of cardiovascular diseases. Results have been reported in patients with stable

coronary artery disease, acute coronary syndrome, stroke, or transient ischemic attack [29–36]. The Scandinavian Simvastatin Survival Study (4S), performed in patients with angina pectoris or previous myocardial infarction and high-serum cholesterol levels, demonstrated that long-term treatment with simvastatin improves survival and decreases cardiovascular events [37]. The Heart Protection Study (HPS; a primary and secondary prevention study) showed that simvastatin significantly reduced cardiovascular mortality and vascular acute events in 20,000 patients with coronary or peripheral vascular disease without hyperlipidemia [38]. The Greek Atorvastatin and Coronary Heart Disease Evaluation, Treating to New Targets (TNT), Aggressive Lipid-Lowering Initiation Abates New Cardiac Events, and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering (IDEAL) studies confirmed a significant decrease of acute cardiovascular events in patients with stable CHD [39, 40]. The Pravastatin or Atorvastatin Evaluation and Infection Therapy, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL), and IDEAL-Acute Coronary Syndromes studies demonstrated the benefits of high-dose-dosage atorvastatin therapy in patients with acute coronary syndromes [40]. In patients with heart failure, the efficacy of statins is still a matter of dispute [41, 42]. In the GISSI-HF trial, rosuvastatin did not reduce death or admission to hospital for cardiovascular reasons in patients with chronic heart failure [42]. The CORONA study partially confirmed these results showing only a reduction of the number of cardiovascular hospitalizations [43]. Statins also improved survival and cardiovascular events in patients after heart transplantation or percutaneous coronary interventions [41] promoting coronary collateral circulation, a modest antihypertensive effect and improving glucose metabolism and insulin sensitivity [44–46]. Although few controversies remain, these clinical studies indicate that: (1) statins should be considered as very promising anti-atherosclerotic drugs (also independently on lowering cholesterol) for secondary prevention in all patients and for primary prevention in high risk individuals (Fig. 1). (2) In persons without traditional cardiovascular risk factors, but with elevated hs-CRP levels, the use of statins might be indicated in the near future. (3) The marked cardiovascular risk reduction might be also related to the direct anti-inflammatory and pleiotropic properties of statins [47–59]. The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III recommended the use of statins for the secondary prevention of cardiovascular diseases as the first-line choice drug for lowering LDL-cholesterol in the high-risk patients [60]. This group includes individuals with established coronary heart disease and diabetes mellitus or with a Framingham 10-year CHD risk greater




Fig. 1 Statin treatment reduces the risk of acute cardiovascular events. Several studies support that statins inhibit atherosclerotic plaque progression and the risk of rupture (primary prevention). These beneficial effects are mediated by statin-induced cholesterol reduction and statin-mediated “pleiotropic” activities. In secondary prevention, the use of statins has been suggested by promising results. However, the prompt restoration of antegrade flow in the infarct-related coronary

artery, whether accomplished pharmacologically or mechanically, remain the mean therapy for improving both left ventricular systolic function and survival during the subsequent hours after the acute myocardial infarction. Further investigations are needed to investigate the possible use of statins to prevent post-ischemic diseases (such as CHF)

than 20%. For primary prevention, the NCEP ATP III recommended to treat individuals with metabolic syndrome and diabetic patients with moderate cardiovascular risk (Framingham 10-year CHD risk of 10–20%) [61]. Treatment with any of the statin family has been associated with transaminase elevations in comparison to placebo [62]. Despite the low frequency (1–2%) of raised aspartate or alanine aminotransferase, these adverse effects are completely reversible and almost never progress to hepatitis or liver failure [63]. A very low risk of neuropathy and gastrointestinal discomfort has been also reported. However, the main risk of statin treatment derives from myotoxicity which ranges from myalgias, creatine kinase elevation to the more serious rhabdomyolysis. This adverse effect has been reported in 1–7% of patients under statin therapy [64]. Itagaki and coworkers recently suggested that myotoxicity could be induced by the same mechanisms governing statin beneficial anti-inflammatory activities. In particular, RhoA dysfunction due to loss of lipid modification with the mevalonate product geranylgeranylpyrophosphate (GGPP) has been observed in statin-induced skeletal muscle toxicity [65]. Further investigations are needed to better clarify the role of intracellular signaling pathways in myotoxicity. Despite these few adverse effects, statins are generally well tolerated. Both second and third generations of statins have been shown to reduce LDL cholesterol more effectively

than first generation without increasing toxicity [66]. In the following, we will discuss on the selective immunomodulatory properties of different statins (Table 1) [67].

Lovastatin

Together with pravastatin and fluvastatin, lovastatin is included in the first generation of statins. Lovastatin represents the drug with the lowest potency and is necessary to use high doses to observe a significant reduction of LDL cholesterol levels [68]. However, lovastatin (together with simvastatin and pravastatin) is less expensive, and it is available in generic formulation. Clinical studies have also confirmed the efficacy of lovastatin in both primary and secondary prevention of cardiovascular diseases. The AFCAPS/TexCAPS study showed that daily treatment with 20–40 mg lovastatin-reduced incidence of acute major cardiac events in comparison with placebo. The study was performed in a middle-aged or elderly population ($n=6,605$) without symptomatic cardiovascular disease [69]. The beneficial effects of lovastatin were confirmed by the ACAPS study that enrolled 919 subjects asymptomatic for clinical cardiovascular disease but with evidence of early carotid atherosclerosis [70]. On the other hand, secondary prevention studies showed that 2–2.5-year therapy with lovastatin-reduced progression of atherosclerosis in dyslipidemic patients with CHD [71–73]. Lovastatin has been also

Table 1 Pharmacokinetic and anti-atherosclerotic activities of statins

Statin	Dose (mg/day)	Lipophilic	Bioavailability (%)	T 1/2 (h)	Protein binding (%)	Cytochrome metabolism	Metabolites	Urinary excretion (%)	Fecal excretion (%)	Anti-atherosclerotic activities			
										Endothelial cells	Leukocytes	Smooth muscle cells	Bone marrow progenitor cells
Lovastatin	10–80	Yes	5	2.9	>95	CYP3A4	Active	10	83	++	++	Not known	+
Pravastatin	5–40	No	18	1.3–2.8	43–55	Sulfatation	Inactive	20	71	+++	++	++	+
Fluvastatin	20–80	Yes	19–29	0.5–2.3	>99	CYP2C9	Inactive	6	90	+++	+	Not known	Not known
Simvastatin	5–80	Yes	5	2–3	94–98	CYP3A4	Active	13	58	+++	+++	+	Not known
Atorvastatin	10–80	Yes	12	15–30	80–90	CYP3A4	Active	2	70	+++	+++	+	+
Rosuvastatin	5–80	No	20	20.8	88	CYP2C9	Active	10	90	++	+	Not known	+

shown to induce in vitro anti-inflammatory activities in different cell types at lower doses. Lovastatin is a potent immunomodulatory and neuroprotective drug. It strongly reduces the migration of monocytes and lymphocytes across in vitro-cultured human blood–brain barrier endothelial cells [74]. Lovastatin also reduces apoptosis and downregulates CD40 expression in TNF-alpha-treated cerebral vascular endothelial cells and in IFN-gamma-treated microglial cells [75, 76]. Lovastatin-induced reduction of transendothelial T cell migration is dependent on the inhibition of rho pathway [77]. Lovastatin directly modulates immune cell functions by both disrupting or upregulating chemokine and chemokine receptor expression [78, 79]. Furthermore, lovastatin inhibits maturation and functional changes of bone marrow-derived dendritic cells [80]. Lovastatin also increases macrophage apoptosis involving the Rac1/Cdc42/JNK pathways [81]. Taken together, these studies support lovastatin as an immunomodulatory therapeutic agent in atherosclerosis and its cerebral complications.

Pravastatin

Pravastatin is the most rigorous tested drug in the “first generation” of statins. Two important primary prevention studies (WOSCOPS and PROSPER) indicated that pravastatin treatment (40 mg/daily) reduced LDL-cholesterol levels, cardiac mortality, and coronary events in comparison with placebo [82, 83]. ALLHAT-LLT study (enrolling 10,355 patients) did not confirm pravastatin-induced reduction in coronary events or mortality [84]. These different results in primary prevention were probably due to the lower reduction of LDL cholesterol levels (–28%) in ALLHAT-LLT study. Furthermore, a strong limitation was represented by the populations, which was exclusively enrolled in developed west countries. To investigate the efficacy of pravastatin in primary cardiovascular prevention in another population, the MEGA study was planned in Japan. Treatment with a low dose (10–20 mg) of pravastatin reduced the risk of coronary heart disease in Japan similarly to that observed in Europe and the USA in the presence of higher doses [85]. Differently from fluvastatin or simvastatin (that are “lipophilic”), pravastatin is a “hydrophilic” compound as the new rosuvastatin and almost not metabolized by the cytochrome P450 complex [86]. Probably for this property, treatment with pravastatin induced different effects in vascular cells. Wiesbauer and coworkers showed that among six different statins, only pravastatin does not decrease PAI-I production in human endothelial cells and smooth muscle cells [87]. Furthermore, pravastatin increases E-selectin and vascular cell adhesion molecule (VCAM)-1-induced expression on vascular endothelial cells stimulated with TNF-alpha or LPS [88]. This study also showed that treatments with simvas-

tatin or fluvastatin increase adhesion molecule expression in TNF- α -stimulated endothelial cells [88]. Therefore, statins might increase TNF- α -mediated proinflammatory activities in endothelial cells. Conversely, pravastatin has been shown to protect mouse cerebral endothelial cells against ceramide-mediated cytotoxicity through vascular endothelial growth factor upregulation and the activation of hypoxia-inducible factor-1 [89]. Furthermore, pravastatin inhibits the production of monocyte chemoattractant protein 1 (MCP-1), interleukin (IL)-6, and IL-8 in irradiated microvascular endothelial cells [90]. These beneficial effects were persistent up to 14 days after irradiation, suggesting that pravastatin could be considered a very promising agent against endothelial dysfunction in patients treated with radiation therapy. These controversial data suggest a still unclear immunomodulatory role of pravastatin on vascular cells. Recent evidence also showed a possible role of pravastatin in vascular endothelial cell protection from oxidative stress. In a rat model of myocardial infarction, Abe and coworkers showed that pravastatin prevented cardiac dysfunction. The suggested mechanism for pravastatin-induced beneficial effects was represented by the inhibition of H₂O₂-mediated caspase-3 activation and endothelial nitric oxide synthase (eNOS) reduction that was observed in cultured vascular endothelial cells [91]. More recently, Suzuki and coauthors showed that pravastatin also improves dysfunctional hibernating myocardium in a swine model of chronic left anterior descending artery (LAD stenosis) [92]. These investigations clearly indicate that improvement after pravastatin administration was exclusively related to mobilization of CD133(+)/cKit(+) bone marrow progenitor cells, without involving endothelial cell function. Controversial immunomodulatory properties of pravastatin have been also shown in immune cells [93]. Pravastatin increases inflammation by activating human peripheral blood mononuclear cells to produce IL-18, TNF- α , and IFN- γ [94]. Furthermore, it increases the phagocytic index of mouse peritoneal macrophages [95]. Conversely, pravastatin induces important immunosuppressive effects by prolonging lung graft survival and inhibiting chronic rejection in renal allograft in rats [96, 97]. Pravastatin treatment also inhibits circulating dendritic cell activation in patients with coronary artery disease [98].

Fluvastatin

Fluvastatin is a lipophilic statin. Differently from other statins that are metabolized by the cytochrome P450 3A4 complex (CYP3A4), fluvastatin is metabolized by another P450 complex [99]. This aspect reduces the risk of pharmacological interactions between fluvastatin and other drugs. Furthermore, it suggests the possible use of

fluvastatin in patients, which are intolerant to second and third generation of statins. The ALERT study investigated the possible reduction of cardiovascular risk in patients who received renal transplant. Fluvastatin treatment reduced cardiac deaths and nonfatal MI but not coronary intervention procedures or mortality in these patients [100]. In two other secondary prevention studies (BCAPS and HYRIM) respectively conducted in patients who had carotid plaque without symptoms of carotid artery disease [101] and hypertensive men [102], fluvastatin-reduced acute cardiovascular events. On the other hand, the Lescol Intervention Prevention Study showed that fluvastatin treatment significantly reduces the risk of adverse cardiac events in patients with average cholesterol levels undergoing their first successful percutaneous coronary intervention [103]. Fluvastatin has been shown to induce cardioprotective effects in both acute and chronic treatments. In a rat model of acute myocardial infarction and reperfusion, the administration of fluvastatin 20 min before the onset of ischemia significantly attenuated the decline of myocardial blood flow, thus, reducing myocardial infarction size [104]. These promising data are in contrast with *in vitro* studies showing that fluvastatin induces cardiac myocyte and vascular endothelial cell apoptosis [105, 106]. Furthermore, it increases the expression of adhesion molecules, MCP-1, and tissue factor in human umbilical vein endothelial cells stimulated by antiphospholipid antibodies [107]. It is possible that fluvastatin exerts its activities in endothelial cells through its uptake into these cells via nonspecific simple diffusion [108]. These apparent negative effects might be counterbalanced by other protective activities induced by fluvastatin in vascular cells. In fact, fluvastatin inhibits matrix metalloproteinase-1 expression and oxidative damage in vascular endothelial cells, thus, improving endothelial dysfunction [109–112]. Fluvastatin also increases prostacyclin production and reduces endothelin-1 secretion in human umbilical vein endothelial cells (HUVEC) contributing to vasodilation and, thus, preventing cardiovascular diseases [113]. At very high concentration (10 μ M), fluvastatin also reduces CRP-induced TNF- α secretion in HUVEC [114]. Despite the important limitation represented by the high dose used, this study supports a direct activity of fluvastatin in the inhibition of CRP-mediated proinflammatory effects. Fluvastatin has been shown to reduce inflammatory cells activation and functions. Mononuclear leukocytes represent the most investigated cell population [115–117]. The anti-inflammatory properties of fluvastatin have been observed in patients with chronic heart failure or allergic asthma [118, 119]. These studies suggest the potential therapeutic use of fluvastatin not only in atherosclerosis but also in other inflammatory diseases.

Simvastatin

Together with atorvastatin, simvastatin has been actively investigated [120], and it has been shown to induce several *in vitro* and *in vivo* beneficial effects to reduce atherosclerotic inflammatory process. Clinical trials in primary and secondary prevention of cardiovascular risk demonstrated the beneficial effects of simvastatin. In primary prevention, the HPS provided direct evidence that cholesterol-lowering therapy-reduced cardiac mortality and coronary events mainly in diabetic subjects without a manifest coronary disease [121]. In secondary prevention, the 4S showed that treatment with simvastatin strongly reduced cardiac mortality and coronary events in comparison to placebo [37]. Simvastatin reduces endothelium dysfunction through a direct benefit on endothelial cells and their precursors [122]. High concentrations of simvastatin (25 μM) reduced TNF- α -mediated apoptosis of endothelial progenitor cells (EPC) [123]. Furthermore, the treatment with 80 mg/day simvastatin for 5 days increases *in vivo* EPC mobilization [124]. Then, simvastatin also promotes endothelial differentiation of bone marrow stromal cells through the Notch signaling pathway [125]. On the other hand, simvastatin might prevent endothelial dysfunction through a direct protective activity on endothelial cells. Simvastatin inhibits CRP-induced CD32, VCAM-1 expression as well as monocyte adhesion to human umbilical vein endothelial cells [126]. Simvastatin treatment also inhibits TNF- α -induced adhesion molecule (selectins) expression on HUVEC [127]. Furthermore, simvastatin protected the vascular endothelium against damages induced by LDL or ox-LDL in rats or a cultured cell line (ECV304 cells) [128]. On the other hand, emerging evidence shows that simvastatin also increases endothelial cell apoptosis suggesting that the clinical benefit of simvastatin in endothelial dysfunction could be due to an unbalance between positive (endothelial cell and endothelial progenitor protection) and negative (endothelial cell apoptosis) activities [129–131]. Simvastatin has been also shown to modulate eNOS in humans and animal models, thus, contributing to reduce endothelial dysfunction [132, 133]. The inflammatory functions of other vascular and immune cell types involved in atherosclerotic processes have been modulated by simvastatin. Simvastatin induces the cytoprotective molecule heme oxygenase-1 in mouse smooth muscle cells *in vivo* and *in vitro* [134]. Treatment with 1 μM simvastatin significantly downregulates chemokine and chemokine receptor expression in human macrophages [135]. These morphological changes result in a reduced locomotory response towards CCL2, as shown *in vivo* by Han and coworkers [136]. More recently, we showed that simvastatin at 1 μM reduces CRP-induced chemokine secretion, ICAM-1 upregulation, and chemotaxis in human

primary monocytes cultured in adherence to polystyrene [137]. In CD14⁺ monocytes, simvastatin reduces toll-like receptor 4 expression suggesting that this drug might directly modulate innate immunity [138]. Neutrophil migration, adherence, and membrane integrity have been also modulated by treatment with simvastatin [139, 140]. Simvastatin also interferes with inflammatory activities mediated by humoral and cell-mediated immunity *in vivo* and *in vitro* [141]. Simvastatin inhibits both human B- and Th1-lymphocyte activation [142–144]. On the other hand, simvastatin promotes Th2-type responses through the direct modulation of dendritic cell function [145]. Accordingly with these data, simvastatin treatment *in vivo* inhibits lymphocyte and NK cell functions and downregulated angiotensin II type 1 receptor on circulating T lymphocytes and monocytes [146, 147].

Atorvastatin

Atorvastatin is the first statin approved to reduce the risk of hospitalization in heart failure patients [148]. Large clinical trials have been performed to assess primary and secondary prevention of cardiovascular diseases. In primary prevention, the ASCOT-LLA and the Collaborative Atorvastatin Diabetes Study showed a significant reduction in cardiovascular events with 10 mg/day atorvastatin in comparison to placebo [27, 149]. In secondary prevention, the majority of clinical studies performed investigated high dose treatments versus low dose. In the TNT and in the IDEAL studies, intensive atorvastatin treatment (80 mg/day) reduced any coronary events in comparison to lower statin doses (respectively 10 mg/day atorvastatin and 20 mg/day simvastatin) in patients with stable coronary artery disease or a history of acute myocardial infarction. In 2001, the MIRACL study further confirmed the need of high-dose atorvastatin therapy to prevent recurrent coronary events in patients with recent acute coronary syndrome. However, in all these studies, no reduction in mortality was observed [30–32, 141–149]. The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 is the only study showing a reduction in mortality in the presence of intensive atorvastatin treatment in secondary prevention of acute cardiovascular events [150]. Chronic treatments with atorvastatin have been shown to induce direct beneficial effects in cardiomyocytes by protecting from hypertrophic cardiomyopathy, cardiac fibrosis, and remodeling, catecholamine deleterious effects in several animal models [151–154]. Several studies investigating the possible effect of atorvastatin in inflammatory diseases have been performed with some controversial results [155–157]. For instance, atorvastatin treatment failed to reduce inflammatory processes in a mouse model systemic lupus erythematosus [157]. Ator-

vastatin has been also shown to directly induce neuroprotection. It reduced neurological deficit by increasing synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury [158]. In the same rat model, atorvastatin also reduced intravascular thrombosis and increased cerebral microvascular integrity [159]. Furthermore, atorvastatin inhibited perihematoma cell death in adult rats after experimental intracerebral hemorrhage [160]. As other statins, atorvastatin directly antagonized inflammatory processes in human brain endothelial cells [161]. The direct neuro and endothelial protective activities of atorvastatin have been shown to reduce stroke consequences in stroke-prone spontaneously hypertensive rats and in a rat model of embolic stroke [162, 163]. These studies strongly suggest that atorvastatin could be a very promising drug with potent anti-inflammatory activities in different diseases. The possible use of atorvastatin to inhibit atherosclerosis represents the best investigated field. Atorvastatin reduced *in vitro* and *in vivo* endothelial dysfunction and inflammatory processes in atherogenesis. As previously indicated for simvastatin, atorvastatin protects endothelium through the increase of endothelial cell progenitor proliferation and mobilization and the induction of vessel wall stabilizing mediators and growth factors in endothelial cells [111, 164–166]. Atorvastatin has been shown to inhibit cytokine-inducible nitric oxide synthase, CD40, CD40L, chemokine, and thrombospondin-1 expression in endothelial cells [167–172]. Atorvastatin also regulates immune cell functions and the release of inflammatory mediators such as CRP. We have recently shown that atorvastatin inhibits CRP production on IL6-treated human hepatocytes [173]. Furthermore, this drug reduces CRP or granulocyte macrophage–colony stimulating factor-mediated proinflammatory activities in human monocytes [137, 174]. Atorvastatin also interferes with T lymphocyte, B lymphocyte, or dendritic cell activation and differentiation [175–179]. Atorvastatin-mediated anti-inflammatory effects have been observed also in clinical studies, investigating inflammatory cardiovascular risk markers in acute coronary syndromes, and coronary artery disease [180, 181]. Further investigations are needed to better assess the role of atorvastatin treatment in the reduction of inflammatory cardiovascular risk factors. Taken together, clinical and basic research studies suggest that high-dose atorvastatin treatments rather than low-dose could be considered as a promising approach to reduce cardiovascular disease.

Rosuvastatin


Rosuvastatin is a synthetic HMG-CoA reductase inhibitor noncompetitive with the cosubstrate nicotinamide-adenine dinucleotide phosphate [182]. Compared to other statins,

rosuvastatin is the most effective to reduce total and LDL-cholesterol levels for mg/dose equivalent. As atorvastatin, rosuvastatin has been shown to additionally bind the enzyme complex not only at the HMG-CoA reductase site [183]. As pravastatin, it is significantly less lipophilic than other statins. Differently from other statins, rosuvastatin is metabolized mainly through CYP2C9 [183]. These pharmacologic and pharmacokinetic aspects support this drug as a very promising candidate to reduce myotoxicity and interaction with other drugs, and improve anti-inflammatory properties. Several clinical studies included in the global GALAXY program have been performed to assess rosuvastatin's clinical efficacy in atherogenic lipid profile, changes in atheroma volume, and cardiovascular morbidity and mortality in different subpopulations [184]. As described above, the recent JUPITER study is the first primary prevention study demonstrating a benefit of statin therapy in individuals with elevated high-sensitivity C-reactive protein levels, but without hyperlipidemia [28]. In secondary prevention, rosuvastatin did not reduce mortality in patients with systolic heart failure and CAD but only the number of cardiovascular hospitalizations. Conversely, the ASTEROID trial demonstrated decrease of percent diameter stenosis and amelioration of minimum lumen diameter in coronary disease patients [185]. Although atherosclerotic lesion regression is not directly related to the reduction of future cardiovascular outcomes, the ASTEROID study strongly supports the possible use of rosuvastatin in secondary prevention. High concentrations of rosuvastatin (100 μ M) suppressed monocyte cell adhesion and ICAM-1, MCP-1, IL-8, IL-6, and COX-2 expression on TNF- α -stimulated HUVEC [186]. Furthermore, although mechanisms have not been identified yet, rosuvastatin treatment protected mice from ischemic stroke [187] and rats from myocardial reperfusion injury [188]. Rosuvastatin also exerts favorable anti-atherosclerotic effects in several animal models [189–192]. These studies suggest that rosuvastatin-mediated benefits are dependent of its antioxidant and anti-inflammatory activity on endothelial cells. A recent study (performed in a small number of patients ($n=48$)) further confirmed the endothelial protective properties of rosuvastatin showing that short-term treatment increases endothelial cell progenitor mobilization [193].

The effects of statins on inflammatory intracellular signaling pathways

Statins have been introduced as HMG-CoA reductase inhibitors to lower LDL-cholesterol synthesis and serum levels (Fig. 2). However, emerging evidence has shown that the “classical” cholesterol pathway could also modulate intracellular signaling pathways involving protein kinases in

Fig. 2 Anti-inflammatory activities of statins depend on both “classical” and “not classical” HMGCoA-Mevalonate pathways. Simplified “classical” and “not classical” HMGCoA-Mevalonate pathways. Statin anti-inflammatory activities depend on the inhibition of both “classical” (HMGCoA–Mevalonate–FPP–cholesterol) and “not classical” (HMGCoA–Mevalonate–FPP–kinase) pathways. Other studies have shown that GGPP may be also involved in the intracellular signaling proteins regulating kinase activation



different cell types. Thus, statins could directly influence vascular and immune cells, hepatocyte, and adipocyte inflammatory functions through the activation of certain intracellular mediators or the inhibition of protein kinase phosphorylation of intracellular second messenger cascades (Fig. 3).

Statin-mediated activation of intracellular pathways

Recently, statins have been shown to directly activate anti-inflammatory intracellular pathways. AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase involved in the regulation of cellular energy




Fig. 3 “Activatory” and “inhibitory” intracellular signaling pathways regulate statin-induced pleiotropic activities. Statins diminish proinflammatory effects and promote anti-inflammatory activities through the direct inhibition/activation of chemokine-, cytokine-, and acute phase reactant-induced intracellular signaling pathways in several cell

types (such as leukocytes, vascular cells, adipocytes, and hepatocytes). In particular, the inhibition of ERK 1/2, rho, JAK/STAT3, or mevalonate pathways is crucial to reduce inflammation. On the other hand, statins directly activates AMPK and PI3K/Akt/NFkB pathways, thus, increasing cell survival, endothelial, and neuronal protection

metabolism. Emerging evidence showed that AMPK might be crucial in vascular protection [194]. Statins directly activates AMPK in different cell types [194, 195]. In particular, statins have been shown to rapidly activate this protein kinase in vitro (cultured HUVEC) and in vivo (mouse aorta and myocardium). Such phosphorylation resulted in eNOS activation that could explain the direct beneficial effects of statins in cardiovascular diseases [196]. Interestingly, statin-mediated AMPK activation was dependent on the upstream activation of PKC-zeta as shown in endothelial cells and in vivo in mice [197]. AMPK-induced eNOS activation also increased endothelial cell progenitor differentiation in endothelial cells indicating a possible protective mechanism on endothelium mediated by statins [198].

On the other hand, the activation of phosphoinositide 3 kinase (PI3K)/Akt (protein kinase B) represents a critical step in inflammatory cell survival, locomotion in atherosclerosis, and cardiovascular disease [199]. Although, few studies (performed with lovastatin) suggested a possible inhibition of PI3K-Akt in endothelial cells [200], there is a general consensus that statins induce cardiovascular protection through the activation of PI3K/Akt pathway. Statin-mediated neuroprotection in animal models of traumatic brain injury and embolic stroke is dependent on PI3K/Akt pathway activation [163, 201, 202]. This pathway involves also the activation of NF- κ B that suppresses caspase-3 and apoptosis cell death [203]. Neuronal nitric oxide synthase upregulation might represent the final effector of this protective pathway [204]. Statin-mediated myocardial protection has been also shown as dependent on PI3K/Akt activation pathway in both in vitro and in vivo models [205–207]. Atherogenesis is also regulated by PI3K/Akt pathway. Statins induce their activation on vascular and immune cells, thus, reducing atherosclerotic lesions in ApoE knockout mice [208] and endothelial dysfunction in type 2 diabetic mice [209]. Controversial results on statin-mediated MAPK phosphorylation have been showed. Statins induce anti-inflammatory activities through both activation and inhibition of these kinases. The statin-induced activation of extracellular signal-regulated kinase (ERK) 1/2 has been observed mainly in immune cells [210, 211]. On the other hand, statins increase macrophage apoptosis through JNK activation [81].

Statin-mediated inhibition of intracellular pathways

As largely discussed, statins have been approved as HMG-CoA reductase inhibitors. The HMG-CoA/mevalonate pathway is essential for cellular metabolism and the formation of precursors of bile acids, lipoproteins and hormones, and nonsterol isoprenoids. These molecules

regulate cell growth and differentiation, gene expression, protein glycosylation, and cytoskeletal assembly [212]. Thus, by influencing cholesterol synthesis, statins not only reduce circulating LDL-cholesterol levels but also induce important cellular modifications which could interfere with immune and thrombotic response. Furthermore, statin reduce mevalonate-derived molecules, such as farnesyl-pyrophosphate (FPP) and GGPP which are essential players in cell signaling, endocytotic/exocytotic transport, and cytoskeleton dynamics [213]. Immune cell functions (including chemotaxis, chemokine secretion, and oxidative metabolism) are regulated by the “classical” mevalonate pathway. Endothelial and smooth muscle cells require this pathway for their proinflammatory functions [213]. Therefore, anti-inflammatory properties of statins might be due to their “classical” pharmacologic properties. Small GTP-binding proteins, which include in the Ras, Rho, Rab, and Ran superfamily, are directly modulated by the mevalonate pathway. These proteins act as molecular “on-off” switches regulating actin cytoskeleton changes in cell adhesion, migration and contraction [214]. They regulate several downstream intracellular messengers, such as protein kinase N, p21-activated protein kinase, and the rho-associated kinases, which control not only cellular locomotion but also cell growth and apoptosis in both immune and vascular cells [215]. Recently, it has been shown that the effects of statins on atherosclerotic processes in the vessel wall and in the brain are partially due to the inhibition of the Rho pathway [216, 217].

Conclusion

Due to their beneficial properties in cardiovascular diseases, statins are among the most widely prescribed medications in the world. Despite some differences between members of the statin family, all these drugs have been shown to reduce cardiovascular events in both primary and secondary prevention. The recent results of the JUPITER Study seem to indicate that statin treatment in CRP-elevated primary prevention markedly reduced cardiovascular events and total mortality. The safety of statins has been largely documented. Beside their well-known lipid lowering effects, statins also affect some immunomodulatory activities. These so called “pleiotropic” effects induce a decrease in pro-inflammatory and an increase in anti-inflammatory molecular pathways. Statin-mediated modulation of molecular intracellular mechanisms in both vascular and immune cells should be considered as a very promising approach to further clarify the statin-induced cardiovascular protection. Beside cardiovascular area, statin therapy is under investigation in other inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis. Many hypotheses have been

already proposed to explain statin anti-inflammatory activities. A strong work is waiting for researchers in the next years.

Acknowledgement This research was funded by EU FP7, Grant number 201668, AtheroRemo and supported by a grant from the Swiss National Science Foundation to Dr. F. Mach (# 310000-118245).

References

1. Yusuf S, Reddy S, Ounpuu S et al (2001) Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 104:2746–2753
2. Yusuf S, Reddy S, Ounpuu S et al (2001) Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation* 104:2855–2864
3. American Heart Association (2002) 2002 Heart and Stroke Statistical Update. American Heart Association, Dallas
4. Wilson PW, D'Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk factor categories. *Circulation* 97:1837–1847
5. Khot UN, Khot MB, Bajzer CT et al (2003) Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA* 290:898–904
6. Root M, Cobb F (2004) Traditional risk factors for coronary heart disease (letter). *JAMA* 291:299
7. Greenland P, Knoll MD, Stamler J et al (2003) Major risk factors as antecedents of fatal and non fatal coronary heart disease events. *JAMA* 290:891–897
8. Carter AM (2005) Inflammation, thrombosis and acute coronary syndromes. *Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res* 2:113–121
9. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. *Nat Rev Immunol* 6:508–519
10. Hansson GK, Libby P, Schönbeck U et al (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. *Circ Res* 91:281–291
11. Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 107:499–511
12. Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. *Am J Med* 116 (Suppl 6A):9S–16S
13. Endo A (2008) A gift from nature: the birth of the statins. *Nat Med* 14:1050–1052
14. Tobert JA, Bell GD, Birtwell J et al (1982) Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. *J Clin Invest* 69:913–919
15. Tobert JA, Hitzengerber G, Kukovetz WR et al (1982) Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. *Atherosclerosis* 41:61–65
16. Hoeg JM, Brewer HB Jr (1987) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. *JAMA* 258:3532–3536
17. Illingworth DR, Bacon S (1987) Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. *Am J Cardiol* 60:33G–42G
18. Mabuchi H, Haba T, Tatami R et al (1981) Effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. *N Engl J Med* 305:478–482
19. Steinberg D (2006) The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the (1984) coronary primary prevention trial ends it—almost. *J Lipid Res* 47:1–14
20. Moride Y, Hegele RA, Langer A et al (2008) Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. *Can J Cardiol* 24:293–300
21. Neil HA, DeMicco DA, Luo D et al (2006) Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). *Diabetes Care* 29:2378–2384
22. Sever PS, Poulter NR (2005) Dahlöf B et al (2005) Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). *Diabetes Care* 28:1151–1157
23. Heart Protection Study Collaborative Group (2007) Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20, 536 people with peripheral arterial disease and other high-risk conditions. *J Vasc Surg* 45:645–654
24. Knopp RH, d'Emden M, Smilde JG et al (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care* 29:1478–1485
25. Thavendiranathan P, Bagai A, Brookhart MA et al (2006) Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. *Arch Intern Med* 166:2307–2313
26. LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *JAMA* 282:2340–2346
27. Sever PS, Dahlöf B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 361:1149–1158
28. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 359:2195–207
29. Pitt B, Waters D, Brown WV et al (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med* 341:70–76
30. LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 352:1425–1435
31. Pedersen TR, Faergeman O, Kastelein JJ et al (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA* 294:2437–2445
32. Schwartz GG, Olsson AG, Ezekowitz MD et al (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 285:1711–1718

33. Liem AH, van Boven AJ, Veeger NJ et al (2002) Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. *Eur Heart J* 23:1931–1937
34. de Lemos JA, Blazing MA, Wiviott SD et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 292:1307–1316
35. Ray KK, Cannon CP, Cairns R et al (2005) Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol* 46:1417–1424
36. Ovbiagele B, Saver JL (2007) Intensive statin therapy after stroke or transient ischemic attack: a SPARCLing success? *Stroke* 38:1110–1112
37. No authors listed (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 344:1383–1389
38. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 360:7–22
39. Arca M (2007) Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. *Drugs* 67(Suppl 1):43–54
40. Arca M, Gasparone A (2007) Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. *Drugs* 67(Suppl 1):29–42
41. Khush KK, Waters DD (2006) Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. *J Card Fail* 12:664–674
42. Investigators Gissi-Hf (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 372:1231–1239
43. Kjekshus J, Apetrei E, Barrios V et al (2007) Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 357:2248–2261
44. Nishikawa H, Miura S, Zhang B et al (2002) Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. *Coron Artery Dis* 13:377–381
45. Borghi C, Veronesi M, Prandin MG et al (2001) Statins and blood pressure regulation. *Curr Hypertens Rep* 3:281–288
46. McFarlane SI, Muniyappa R, Francisco R et al (2002) Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. *J Clin Endocrinol Metab* 87:1451–1458
47. Inami N, Nomura S, Shouzu A et al (2007) Effects of pitavastatin on adiponectin in patients with hyperlipidemia. *Pathophysiol Haemost Thromb* 36:1–8
48. Kinlay S, Schwartz GG, Olsson AG et al (2008) Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. *Arterioscler Thromb Vasc Biol* 28:142–147
49. Vlachopoulos C, Aznaouridis K, Dagher A et al (2007) Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. *Eur Heart J* 28:2102–2109
50. Blanco-Colio LM, Martín-Ventura JL, de Teresa E et al (2007) Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. *Am Heart J* 153:881–888
51. Pignatelli P, Sanguigni V, Lenti L et al (2007) Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. *J Thromb Haemost* 5:1170–1178
52. Hanefeld M, Marx N, Pfützner A et al (2007) Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. *J Am Coll Cardiol* 49:290–297
53. Goicoechea M, de Vinuesa SG, Lahera V et al (2006) Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. *J Am Soc Nephrol* 17: S231–S235
54. Patti G, Chello M, Pasceri V et al (2006) Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. *J Am Coll Cardiol* 48:1560–1566
55. Muhlestein JB, May HT, Jensen JR et al (2006) The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. *J Am Coll Cardiol* 48:396–401
56. Sola S, Mir MQ, Lerakis S et al (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. *J Am Coll Cardiol* 47:332–337
57. Macin SM, Perna ER, Farias EF et al (2005) Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. *Am Heart J* 149:451–457
58. Blanco-Colio LM, Martín-Ventura JL, de Teresa E et al (2007) Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. *Arterioscler Thromb Vasc Biol* 27:168–174
59. Arnaud C, Braunersreuther V, Mach F (2005) Toward immunomodulatory and anti-inflammatory properties of statins. *Trends Cardiovasc Med* 15:202–206
60. Hennekens CH, Hollar D, Eidelman RS et al (2006) Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. *MedGenMed* 8:54
61. Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 110:227–239
62. Kashani A, Phillips CO, Foody JM et al (2006) Risks associated with statin therapy: a systematic overview of randomized clinical trials. *Circulation* 114:2788–2797
63. Shepherd J (2006) Who should receive a statin these days? Lessons from recent clinical trials. *J Intern Med* 260:305–319
64. Christopher-Stine L (2006) Statin myopathy: an update. *Curr Opin Rheumatol* 18:647–653
65. Itagaki M, Takaguri A, Kano S et al (2009) Possible mechanisms underlying statin-induced skeletal muscle toxicity in I6 fibroblasts and in rats. *J Pharmacol Sci* 109:94–101
66. Vaughan CJ, Gotto AM Jr (2004) Update on statins: 2003. *Circulation* 110:886–892
67. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. *Circulation* 109:III50–III57
68. Jones P, Kafonek S, Laurora I et al (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). *Am J Cardiol* 81:582–587
69. Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. *Air*

- Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 279:1615–1622
70. Furberg CD, Adams HP Jr, Applegate WB et al (1994) Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. *Circulation* 90:1679–1687
 71. Zhao XQ, Brown BG, Hillger L et al (1993) Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. *Circulation* 88:2744–2753
 72. Blankenhorn DH, Azen SP, Krams DM et al (1993) Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). *Ann Intern Med* 119:969–976
 73. Waters D, Higginson L, Gladstone P et al (1995) Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. *Circulation* 92:2404–2410
 74. Ifergan I, Wosik K, Cayrol R et al (2006) Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. *Ann Neurol* 60:45–55
 75. Lin R, Liu J, Peng N et al (2006) Lovastatin reduces apoptosis and downregulates the CD40 expression induced by TNF- α in cerebral vascular endothelial cells. *Curr Neurovasc Res* 3:41–47
 76. Townsend KP, Shytle DR, Bai Y et al (2004) Lovastatin modulation of microglial activation via suppression of functional CD40 expression. *J Neurosci Res* 78:167–76
 77. Greenwood J, Walters CE, Pryce G et al (2003) Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. *FASEB J* 17:905–7
 78. Nabatov AA, Pollakis G, Linnemann T et al (2007) Statins disrupt CCR5 and RANTES expression levels in CD4⁺ T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. *PLoS ONE* 2:e470
 79. Mira E, León B, Barber DF et al (2008) Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. *J Immunol* 181:3524–3534
 80. Sun D, Fernandes G (2003) Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. *Cell Immunol* 223:52–62
 81. Liang SL, Liu H, Zhou A (2006) Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. *J Immunol* 177:651–656
 82. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) (1998) *Circulation* 97:1440–1445
 83. Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 360:1623–1630
 84. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 288:2998–3007
 85. Nakamura H, Arakawa K, Itakura H et al (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet* 368:1155–1163
 86. Tanaka T, Porter CM, Horvath-Arcidiacono JA et al (2007) Lipophilic statins suppress cytotoxicity by freshly isolated natural killer cells through modulation of granule exocytosis. *Int Immunol* 19:163–173
 87. Wiesbauer F, Kaun C, Zorn G et al (2002) HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. *Br J Pharmacol* 135:284–292
 88. Dimitrova Y, Dunoyer-Geindre S, Reber G et al (2003) Effects of statins on adhesion molecule expression in endothelial cells. *J Thromb Haemost* 1:2290–2299
 89. Chen SD, Hu CJ, Yang DI et al (2005) Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. *Ann N Y Acad Sci* 1042:357–364
 90. Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC, Benderitter M et al (2005) Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. *Radiat Res* 163:479–487
 91. Abe Y, Izumi T, Urabe A et al (2006) Pravastatin prevents myocardium from ischemia-induced fibrosis by protecting vascular endothelial cells exposed to oxidative stress. *Cardiovasc Drugs Ther* 20:273–280
 92. Suzuki G, Iyer V, Cimato T et al (2008) Pravastatin Improves Function in Hibernating Myocardium by Mobilizing CD133⁺ and cKit⁺ Bone Marrow Progenitor Cells and Promoting Myocytes to Reenter the Growth Phase of the Cardiac Cell Cycle. *Circ Res* 104(2):255–264. doi:10.1161/CIRCRESAHA.108.188730
 93. Kwak B, Mulhaupt F, Myit S et al (2000) Statins as a newly recognized type of immunomodulator. *Nat Med* 6:1399–1402
 94. Takahashi HK, Mori S, Iwagaki H et al (2005) Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. *J Leukoc Biol* 77:400–407
 95. Djalalati M, Salman H, Bergman M et al (2006) Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. *Exp Mol Pathol* 2006(80):160–164
 96. Li Y, Köster T, Mörike C et al (2006) Pravastatin prolongs graft survival in an allogeneic rat model of orthotopic single lung transplantation. *Eur J Cardiothorac Surg* 30:515–524
 97. Ji P, Si MS, Podnos Y et al (2002) Prevention of chronic rejection by pravastatin in a rat kidney transplant model. *Transplantation* 74:821–827
 98. Li X, Liu C, Cui J et al (2009) Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease. *Basic Clin Pharmacol Toxicol* 104:101–106
 99. Kapur NK, Musunuru K (2008) Clinical efficacy and safety of statins in managing cardiovascular risk. *Vasc Health Risk Manag* 4:341–353
 100. Holdaas H, Fellström B, Jardine AG et al (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 361:2024–2031
 101. Hedblad B, Wikstrand J, Janzon L et al (2001) Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). *Circulation* 103:1721–1726
 102. Anderssen SA, Hjelstuen AK, Hjermann I et al (2005) Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. *Atherosclerosis* 178:387–397
 103. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B, Lescol Intervention Prevention Study (LIPS) Investigators (2002) Fluvastatin for prevention of cardiac events following successful

- first percutaneous coronary intervention: a randomized controlled trial. *JAMA* 287:3215–3222
104. Tiefenbacher CP, Kapitzka J, Dietz V et al (2003) Reduction of myocardial infarct size by fluvastatin. *Am J Physiol Heart Circ Physiol* 285:H59–H64
 105. Ogata Y, Takahashi M, Takeuchi K et al (2002) Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. *J Cardiovasc Pharmacol* 40:907–915
 106. Newton CJ, Xie YX, Burgoyne CH et al (2003) Fluvastatin induces apoptosis of vascular endothelial cells: blockade by glucocorticoids. *Cardiovasc Surg* 11:52–60
 107. Dunoyer-Geindre S, Dimitrova Y, Fish RJ et al (2005) Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. *Thromb Haemost* 93:339–345
 108. Ohtawa M, Masuda N, Akasaka I et al (1999) Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. *Br J Clin Pharmacol* 47:383–389
 109. Ikeda U, Shimpo M, Ohki R et al (2000) Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. *Hypertension* 36:325–329
 110. Xu SZ, Zhong W, Watson NM et al (2008) Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. *J Thromb Haemost* 6:692–700
 111. Lopez S, Peiretti F, Bonardo B et al (2000) Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. *Atherosclerosis* 152:359–366
 112. Haruna Y, Morita Y, Yada T et al (2007) Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. *Arthritis Rheum* 56:1827–1835
 113. Seeger H, Mueck AO, Lippert TH (2000) Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. *Int J Clin Pharmacol Ther* 38:270–272
 114. Wang HR, Li JJ, Huang CX et al (2005) Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. *Clin Chim Acta* 353:53–60
 115. Niwa S, Totsuka T, Hayashi S (1996) Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. *Int J Immunopharmacol* 18:669–675
 116. Hillyard DZ, Jardine AG, McDonald KJ et al (2004) Fluvastatin inhibits raft dependent Fcγ receptor signaling in human monocytes. *Atherosclerosis* 172:219–228
 117. Montero MT, Hernández O, Suárez Y et al (2000) Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. *Atherosclerosis* 153:303–313
 118. Földes G, von Haehling S, Okonko DO et al (2008) Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. *Int J Cardiol* 124:80–85
 119. Samson KT, Minoguchi K, Tanaka A et al (2006) Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. *Clin Exp Allergy* 36:475–482
 120. Kolovou GD, Katerina A, Ioannis V et al (2008) Simvastatin: two decades in a circle. *Cardiovasc Ther* 26:166–178
 121. Collins R, Armitage J, Parish S et al (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 361:2005–2016
 122. Hernández-Perera O, Pérez-Sala D, Soria E, Lamas S (2000) Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. *Circ Res* 87:616–622
 123. Henrich D, Seebach C, Wilhelm K et al (2007) High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. *J Surg Res* 142:13–19
 124. Spiel AO, Mayr FB, Leitner JM et al (2008) Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. *Thromb Res* 123:108–113
 125. Xu J, Liu X, Chen J et al (2008) Simvastatin enhances bone marrow stromal cell differentiation into endothelial cells via Notch signaling pathway. *Am J Physiol Cell Physiol* 296(3): C535–C543. doi:10.1152/ajpcell.00310.2008
 126. Liang YJ, Shyu KG, Wang BW et al (2008) Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. *Cardiology* 110:182–190
 127. Eccles KA, Sowden H, Porter KE et al (2008) Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. *Atherosclerosis* 200:69–79
 128. Jiang JL, Jiang DJ, Tang YH et al (2004) Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor. *Acta Pharmacol Sin* 25:893–901
 129. Schaefer CA, Kuhlmann CR, Weiterer S et al (2006) Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation. *Atherosclerosis* 185:290–296
 130. Tang D, Park HJ, Georgescu SP et al (2006) Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. *Life Sci* 79:1484–1492
 131. Taraseviciene-Stewart L, Scerbavicius R, Choe KH et al (2006) Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* 291:L668–L676
 132. Chen H, Ren JY, Xing Y, Zhang WL, Liu X, Wu P, Wang RJ, Luo Y (2009) Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. *Int J Cardiol* 131:313–320
 133. Naoum JJ, Zhang S, Woodside KJ, Song W, Guo Q, Belalcazar LM, Hunter GC (2004) Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin. *Surgery* 136:323–328
 134. Lee TS, Chang CC, Zhu Y et al (2004) Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. *Circulation* 110:1296–1302
 135. Veillard NR, Braunersreuther V, Arnaud C et al (2006) Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. *Atherosclerosis* 188:51–58
 136. Han KH, Ryu J, Hong KH et al (2005) HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. *Circulation* 111:1439–1447
 137. Montecucco F, Burger F, Pelli G et al (2009) Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. *Rheumatology (Oxford)* 48(3):233–242. doi:10.1093/rheumatology/ken466
 138. Ulivieri C, Fanigliulo D, Benati D et al (2008) Simvastatin impairs humoral and cell-mediated immunity in mice by

- inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation. *Eur J Immunol* 38:2832–2844
139. Day AP, Bellavia S, Jones OT et al (1997) Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity. *Ann Clin Biochem* 34:269–275
 140. Deskur-Smielecka E, Wykretowicz A, Banaszak A et al (2000) The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils. *Int J Cardiol* 75:85–90
 141. Methe H, Kim JO, Kofler S et al (2005) Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14⁺ monocytes. *Arterioscler Thromb Vasc Biol* 25:1439–1445
 142. Rudich SM, Mongini PK, Perez RV et al (1998) HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. *Transplant Proc* 30:992–995
 143. Zhang X, Jin J, Peng X, Ramgolam VS et al (2008) Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4⁺ lymphocytes. *J Immunol* 180:6988–6996
 144. Ghittoni R, Patrussi L, Pirozzi K et al (2005) Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. *FASEB J* 19:605–607
 145. Arora M, Chen L, Paglia M et al (2006) Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. *Proc Natl Acad Sci USA* 103:7777–7782
 146. Hillyard DZ, Cameron AJ, McDonald KJ et al (2004) Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. *Atherosclerosis* 175:305–313
 147. Marino F, Guasti L, Cosentino M et al (2008) Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. *J Hypertens* 26:1147–1155
 148. Khush KK, Waters DD, Bittner V et al (2007) Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. *Circulation* 115:576–583
 149. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 364:685–696
 150. Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 350:1495–1504
 151. Liao Y, Zhao H, Ogai A et al (2008) Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. *Hypertens Res* 31:335–344
 152. Bezerra DG, Lacerda Andrade LM et al (2008) Atorvastatin attenuates cardiomyocyte loss in adult rats from protein-restricted dams. *J Card Fail* 14:151–160
 153. Senthil V, Chen SN, Tsybouleva N et al (2005) Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. *Circ Res* 97:285–292
 154. Schmechel A, Grimm M, El-Armouche A et al (2009) Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. *Cardiovasc Res* 82(1):100–106
 155. Grip O, Janciauskiene S, Lindgren S (2004) Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. *Inflamm Bowel Dis* 10:193–200
 156. Thomas PB, Albini T, Giri RK et al (2005) The effects of atorvastatin in experimental autoimmune uveitis. *Br J Ophthalmol* 89:275–279
 157. Graham KL, Lee LY, Higgins JP et al (2008) Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. *Arthritis Rheum* 58:2098–2104
 158. Lu D, Goussev A, Chen J, Pannu P et al (2004) Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. *J Neurotrauma* 21:21–32
 159. Lu D, Mahmood A, Goussev A et al (2004) Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. *J Neurosurg* 101:813–821
 160. Jung KH, Chu K, Jeong SW et al (2004) HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. *Stroke* 35:1744–1749
 161. Buttman M, Lorenz A, Weishaupt A et al (2007) Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration. *J Neurochem* 102:1001–1008
 162. Tanaka N, Katayama Y, Katsumata T et al (2007) Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. *Brain Res* 1169:125–132
 163. Zhang L, Zhang ZG, Liu XS et al (2007) The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat. *Arterioscler Thromb Vasc Biol* 27:2470–2475
 164. Assmus B, Urbich C, Aicher A et al (2003) HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. *Circ Res* 92:1049–1055
 165. Imanishi T, Hano T, Sawamura T et al (2004) Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. *Clin Exp Pharmacol Physiol* 31:407–413
 166. Soehnlein O, Eskafi S, Schmeisser A et al (2004) Atorvastatin induces tissue transglutaminase in human endothelial cells. *Biochem Biophys Res Commun* 322:10510–10519
 167. Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. *Br J Pharmacol* 136:143–149
 168. Wagner AH, Gebauer M, Gülden-zoph B et al (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. *Arterioscler Thromb Vasc Biol* 22:1784–1789
 169. Mulhaupt F, Matter CM, Kwak BR et al (2003) Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. *Cardiovasc Res* 59:755–766
 170. Schönbeck U, Gerdes N, Varo N et al (2002) Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. *Circulation* 106:2888–2893
 171. Zineh I, Luo X, Welder GJ et al (2006) Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. *Pharmacotherapy* 26:333–340
 172. Martínez-Sales V, Vila V, Ferrando M et al (2007) Atorvastatin neutralizes the up-regulation of thrombospondin-1 induced by thrombin in human umbilical vein endothelial cells. *Endothelium* 14:233–238
 173. Arnaud C, Burger F, Steffens S et al (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes:

- new evidence for direct antiinflammatory effects of statins. *Arterioscler Thromb Vasc Biol* 25:1231–1236
174. Tanimoto A, Murata Y, Wang KY et al (2008) Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. *J Biol Chem* 283:4643–4651
 175. Kofler S, Schlichting C, Jankl S et al (2008) Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion. *Atherosclerosis* 197:105–110
 176. Shimada K, Miyauchi K, Daida H (2004) Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. *Circulation* 109:e213–e214
 177. Dunn SE, Youssef S, Goldstein MJ et al (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. *J Exp Med* 203:401–412
 178. Coward W, Chow SC (2006) Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation. *Atherosclerosis* 186:302–309
 179. Lawman S, Mauri C, Jury EC et al (2004) Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. *J Immunol* 173:7641–7646
 180. Xu ZM, Zhao SP, Li QZ et al (2003) Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. *Clin Chim Acta* 338:17–24
 181. Smith C, Halvorsen B, Otterdal K et al (2008) High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. *Cardiovasc Res* 79:195–203
 182. McTaggart F, Buckett L, Davidson R et al (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. *Am J Cardiol* 87:28B–32B
 183. White CM (2002) A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. *J Clin Pharmacol* 42:963–970
 184. Schuster H (2007) The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. *Expert Rev Cardiovasc Ther* 5:177–193
 185. Ballantyne CM, Raichlen JS, Nicholls SJ et al (2008) Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. *Circulation* 117:2458–2466
 186. Kim YS, Ahn Y, Hong MH et al (2007) Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. *J Cardiovasc Pharmacol* 49:376–383
 187. Ikeda Y, Young LH, Lefer AM (2003) Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. *J Cardiovasc Pharmacol* 41:649–656
 188. Laufs U, Gertz K, Dirnagl U et al (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. *Brain Res* 942:23–30
 189. Schäfer K, Kaiser K, Konstantinides S (2005) Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. *Thromb Haemost* 93:145–152
 190. Miersch S, Sliskovic I, Raturi A et al (2007) Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. *Free Radic Biol Med* 42:270–279
 191. Desjardins F, Sekkali B, Verreth W et al (2008) Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. *Eur Heart J* 29:128–137
 192. Enomoto S, Sata M, Fukuda D et al (2009) Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. *Biomed Pharmacother* 63:19–26
 193. Pirro M, Schillaci G, Romagno PF et al (2009) Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function. *J Cardiovasc Pharmacol Ther* 14(1):14–21
 194. Zou MH, Wu Y (2008) AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. *Clin Exp Pharmacol Physiol* 35:535–545
 195. McCarty MF (2004) AMPK activation may suppress hepatic production of C-reactive protein by stimulating nitric oxide synthase. *Med Hypotheses* 63:328–333
 196. Sun W, Lee TS, Zhu M et al (2006) Statins activate AMP-activated protein kinase in vitro and in vivo. *Circulation* 114:2655–2662
 197. Choi HC, Song P, Xie Z et al (2008) Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. *J Biol Chem* 283:20186–20197
 198. Li X, Han Y, Pang W et al (2008) AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. *Arterioscler Thromb Vasc Biol* 28:1789–1795
 199. Besler C, Doerries C, Giannotti G et al (2008) Pharmacological approaches to improve endothelial repair mechanisms. *Expert Rev Cardiovasc Ther* 6:1071–1082
 200. Prasad R, Giri S, Nath N et al (2005) Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction. *J Neurochem* 94:204–214
 201. Prinz V, Laufs U, Gertz K, Endres M et al (2008) Intravenous rosuvastatin for acute stroke treatment: an animal study. *Stroke* 39:433–438
 202. Wu H, Lu D, Jiang H et al (2008) Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. *J Neurotrauma* 25:130–139
 203. Wu H, Lu D, Jiang H et al (2008) Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. *J Neurosurg* 109:691–698
 204. Nakata S, Tsutsui M, Shimokawa H et al (2007) Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway. *Arterioscler Thromb Vasc Biol* 27:92–98
 205. Kobayashi N, Takeshima H, Fukushima H et al (2009) Cardio-protective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts. *Am J Hypertens* 22:176–182
 206. Cheng CF, Juan SH, Chen JJ et al (2008) Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. *Apoptosis* 13:883–894
 207. Ye Y, Lin Y, Atar S et al (2006) Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. *Am J Physiol Heart Circ Physiol* 291: H1158–H1169
 208. Schroeter MR, Humboldt T, Schäfer K et al (2008) Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. *Atherosclerosis* doi:10.1016/j.atherosclerosis.2008.11.013
 209. Takenouchi Y, Kobayashi T, Matsumoto T et al (2008) Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice. *J Pharmacol Sci* 106:600–608
 210. Waiczies S, Prozorovski T, Infante-Duarte C et al (2005) Atorvastatin induces T cell anergy via phosphorylation of ERK1. *J Immunol* 174:5630–5635

211. Merla R, Ye Y, Lin Y et al (2007) The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. *Am J Physiol Heart Circ Physiol* 293:H1918–H1928
212. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. *Nature* 343:425–430
213. Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. *Clin Biochem* 40:575–584
214. Narumiya S, Ishizaki T, Watanabe N (1997) Rho effectors and reorganization of actin cytoskeleton. *FEBS Lett* 410:68–72
215. Noma K, Oyama N, Liao JK (2006) Physiological role of ROCKs in the cardiovascular system. *Am J Physiol Cell Physiol* 290:C661–C668
216. Tramontano AF, O’Leary J, Black AD et al (2004) Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. *Biochem Biophys Res Commun* 320:34–38
217. Chrissobolis S, Sobey CG (2006) Recent evidence for an involvement of rho-kinase in cerebral vascular disease. *Stroke* 37:2174–2180